Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 7/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.37 |
| ▸ | BRD4 | O60885 | 8/20 | 0.37 |
| ▸ | BRD2 | P25440 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23107036 | 1.00 | SRD5A1 (0.44) | SRD5A1SRD5A2BRD4BRD2TACR1 | |
| SCHEMBL24456727 | 1.00 | SRD5A1 (0.44) | SRD5A1SRD5A2BRD4BRD2TACR1 | |
| SCHEMBL23707186 | 0.82 | SRD5A1 (0.41) | SRD5A1SRD5A2BRD4BRD2TACR1 | |
| SCHEMBL21254092 | 0.82 | BRD4 (0.45) | SRD5A1SRD5A2BRD4BRD2 | |
| SCHEMBL18883352 | 0.78 | BRD4 (0.47) | SRD5A1BRD4DDB1CRBN | |
| SCHEMBL18821181 | 0.78 | BRD4 (0.47) | SRD5A1BRD4DDB1CRBN | |
| SCHEMBL7905602 | 0.78 | BRD4 (0.47) | SRD5A1BRD4DDB1CRBN | |
| SCHEMBL13024157 | 0.78 | ACE (0.32) | — | |
| SCHEMBL9255662 | 0.78 | MAPT (0.43) | — | |
| SCHEMBL29333362 | 0.75 | SRD5A1 (0.42) | SRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2023235880-A1 | CD38 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. (US) | 2023-12-07 | — | — | WO | disclosed |
| US-11787780-B2 | Quaternary indazole glucocorticoid receptor antagonists | CORCEPT THERAPEUTICS INCORPORATED (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787780-B2 | Quaternary indazole glucocorticoid receptor antagonists | CORCEPT THERAPEUTICS INCORPORATED (US) | 2023-10-17 | — | — | US | disclosed |
| EP-3724188-B1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230117631-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. | 2023-04-20 | — | — | US | disclosed |
| WO-2023014908-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | Pipeline Therapeutics, Inc. (US) | 2023-02-09 | — | — | WO | disclosed |
| US-20230032612-A1 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2023-02-02 | — | — | US | disclosed |
| US-20230012362-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY | 2023-01-12 | — | — | US | disclosed |
| US-20160229831-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160151369-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-06-02 | — | — | US | disclosed |
| US-9133154-B2 | Substituted 3-phenylpropylamine derivatives for the treatment of ophthalmic diseases and disorders | ACUCELA INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140275043-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2010123451-A1 | SULPHIDE BRIDGED DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2010-10-28 | — | — | WO | disclosed |
| US-4880901-A | DICHLOROAROMATICS WITH SODIUM SULFIDE AND ONE TRIHALOAROMATIC, INJECTION MOLDING | PHILLIPS PETROLEUM COMPANY (US) | 1989-11-14 | — | — | US | disclosed |
| EP-0100551-B1 | ARYLENE SULFIDE TERPOLYMERS AND PROCESSES FOR MAKING THEM | PHILLIPS PETROLEUM COMPANY (US) | 1987-07-15 | — | — | EP | disclosed |
| EP-0100551-A2 | Arylene sulfide terpolymers and processes for making them | PHILLIPS PETROLEUM COMPANY (US) | 1984-02-15 | — | — | EP | disclosed |
| US-4405767-A | ALKALI METAL SULFIDE, N-ALKYL LACTAM AND A POLYHALOAROMATIC COMPOUND | PHILLIPS PETROLEUM COMPANY (US) | 1983-09-20 | — | — | US | disclosed |
| US-4116947-A | FROM P-DIHALOBENZENE, POLYHALO AROMATIC COMPOUND, ALKALI METAL SULFIDE, N-ALKYL LACTAM AND WATER | PHILLIPS PETROLEUM COMPANY (US) | 1978-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787780-B2 | Quaternary indazole glucocorticoid receptor antagonists | NR3C1, NR3C2, MC2R | SRD5A1 70/4885SRD5A2 54/4885BRD4 1072/4885 |
| US-20140275043-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, PSEN2, CLN6 | SRD5A1 1481/4885SRD5A2 2012/4885BRD4 1317/4885 |
| US-20230032612-A1 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, MC2R | SRD5A1 70/4885SRD5A2 54/4885BRD4 1072/4885 |
| US-20160229831-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, PSEN2, CLN6 | SRD5A1 1481/4885SRD5A2 2012/4885BRD4 1317/4885 |
| US-20230117631-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | SRD5A1 1787/4885SRD5A2 1879/4885BRD4 2720/4885 |
| US-20230012362-A1 | WDR5 INHIBITORS AND MODULATORS | WDR5, WDR1, WDR77 | SRD5A1 2573/4885SRD5A2 3257/4885BRD4 44/4885 |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | SRD5A1 1787/4885SRD5A2 1879/4885BRD4 2720/4885 |
| US-20160151369-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, PSEN2, CLN6 | SRD5A1 1481/4885SRD5A2 2012/4885BRD4 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.